Interferon alfa-2a

Type I Interferon CytokineRx: PrescriptionCompound: Approved

Also known as: IFN-α2a, IFN‑A2a, IFN‑α2a, Interferon alpha-2a, NSC-367982, Pegasys, rIFN-α2a, Roferon-A, Roferon‑A

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Source Interferon alfa-2a at Peptiology

Save 10% with code PEPTI-BOSSRABBIT-10

Shop Now & Save 10% →

Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.

Summary

Recombinant human interferon‑α2a used as an antiviral and antineoplastic agent for chronic hepatitis C/B, certain leukemias, and melanoma.

Mechanism of Action

Binds interferon‑α receptor (IFNAR1/2) → activates JAK1/TYK2 → STAT1/2 phosphorylation → transcription of interferon‑stimulated genes; confers antiviral, antiproliferative, and immunomodulatory effects.

Routes of Administration

IntramuscularIntravenousSubcutaneous

Goals & Uses

  • AIDS-Related Kaposi's SarcomaOncology / Infectious DiseaseModerate
  • Chronic Hepatitis C Antiviral TreatmentInfectious Disease / AntiviralHigh
  • Melanoma (adjuvant)OncologyModerate
  • Chronic hepatitis CAntiviralHigh
  • Hairy‑cell leukemiaAntineoplasticHigh
  • Antiviral ImmunomodulationImmunologyModerate
  • Chronic myelogenous leukemia (CML)OncologyHigh
  • Hairy cell leukemia treatmentOncologyHigh
  • Chronic hepatitis BAntiviral / HepatologyModerate
  • Follicular LymphomaOncologyModerate

Contraindications

  • Severe Psychiatric Disorders (e.g., severe depression, suicidality)PsychiatricHigh
  • Hypersensitivity to interferon alfa or formulation componentsImmunologicHigh
  • Known hypersensitivity to interferon‑α2a or excipientsAllergyHigh
  • Severe autoimmune diseaseImmunologicalHigh
  • PregnancyPopulationHighPotential fetal risk or insufficient safety data
  • Neonates and Infants (benzyl alcohol-containing formulations)PediatricHigh
  • Severe depression or psychiatric illnessPsychiatricModerate
  • Autoimmune hepatitisHepatic / AutoimmuneHigh
  • Decompensated liver diseaseHepatic ImpairmentHigh

Adverse Effects

  • Depression / suicidal ideationPsychiatricModerate
  • Injection site reactionsLocalCommon
  • ThrombocytopeniaHematologicCommonLow platelet count
  • Hepatotoxicity / Transaminase ElevationHepaticCommon
  • NeutropeniaHematologicCommonLow neutrophil count
  • Myelosuppression (neutropenia, thrombocytopenia, anemia)HematologicCommon
  • Flu‑like syndrome (fever, myalgia, fatigue)SystemicCommon
  • Elevated liver enzymesHepaticCommonIncrease in AST/ALT or other hepatic markers
  • Flu-like SyndromeSystemic / ConstitutionalCommon
  • Thyroid dysfunction (hypo- or hyperthyroidism)EndocrineUncommon
  • Neuropsychiatric Effects (depression, irritability, suicidality)Psychiatric / NeurologicalCommon

Drug Interactions

  • Live attenuated vaccinesHigh
  • Zidovudine (AZT)High
  • Immunosuppressants (e.g., cyclosporine)Moderate
  • RibavirinModerate
  • ClozapineHigh
  • TheophyllineModerate
  • MethadoneModerate

Population Constraints

  • PregnancyReproductive SafetyRelative
  • Cardiac DiseaseCardiovascularRelative
  • Renal impairmentOrgan ImpairmentRelative
  • Pediatric patientsAgeRelative
  • Pre-existing Psychiatric ConditionsPsychiatricRelative
  • Elderly patientsAgeRelative
  • Pregnant womenReproductiveAbsolute
  • Pediatric patients (<1 yr)AgeRelative

Regulatory Status

  • European UnionApprovedApproved: Chronic hepatitis C, Chronic hepatitis B, Hairy-cell leukemia, MelanomaEMA approval; similar indications as US.
  • United StatesApprovedApproved: Chronic hepatitis C, Hairy-cell leukemia, Melanoma (adjuvant)FDA approval under brand Roferon‑A; pegylated form (Pegasys) also approved.
  • United KingdomApprovedApproved: Chronic hepatitis C, Hairy-cell leukemia, MelanomaMHRA approval.

FDA‑approved (Roferon‑A) for hepatitis C (in combination with ribavirin), hairy‑cell leukemia, and melanoma; also approved in EU and UK.

Evidence & Sources

No sources recorded yet.

Frequently Asked Questions

What is Interferon alfa-2a?

Recombinant human interferon‑α2a used as an antiviral and antineoplastic agent for chronic hepatitis C/B, certain leukemias, and melanoma.

What is Interferon alfa-2a used for?

Interferon alfa-2a is educationally associated with: AIDS-Related Kaposi's Sarcoma, Chronic Hepatitis C Antiviral Treatment, Melanoma (adjuvant), Chronic hepatitis C, Hairy‑cell leukemia, Antiviral Immunomodulation, Chronic myelogenous leukemia (CML), Hairy cell leukemia treatment, Chronic hepatitis B, Follicular Lymphoma. Educational only — not medical advice.

How is Interferon alfa-2a administered?

Recorded routes of administration: Intramuscular, Intravenous, Subcutaneous.

What are the potential side effects of Interferon alfa-2a?

Reported adverse effects include: Depression / suicidal ideation, Injection site reactions, Thrombocytopenia, Hepatotoxicity / Transaminase Elevation, Neutropenia, Myelosuppression (neutropenia, thrombocytopenia, anemia), Flu‑like syndrome (fever, myalgia, fatigue), Elevated liver enzymes, Flu-like Syndrome, Thyroid dysfunction (hypo- or hyperthyroidism), Neuropsychiatric Effects (depression, irritability, suicidality). This list is not exhaustive — consult a qualified clinician.

Who should avoid Interferon alfa-2a?

Recorded contraindications: Severe Psychiatric Disorders (e.g., severe depression, suicidality), Hypersensitivity to interferon alfa or formulation components, Known hypersensitivity to interferon‑α2a or excipients, Severe autoimmune disease, Pregnancy, Neonates and Infants (benzyl alcohol-containing formulations), Severe depression or psychiatric illness, Autoimmune hepatitis, Decompensated liver disease. Consult a qualified clinician before use.

More in this class